Background-The present substudy of a recently published randomized trial aimed to investigate the effect of intramyocardial bone marrow cell injection on diastolic function in patients with chronic myocardial ischemia. Methods and Results-In a total of 50 patients, diastolic function was evaluated before and 3 months after bone marrow cell injection using standard echocardiography and strain analysis. In addition, MRI-derived transmitral flow measurements were obtained in a subset of 36 patients. Left ventricular ejection fraction increased from 50Ϯ5% to 54Ϯ7% in the bone marrow cell group, which was a significant improvement as compared with the placebo group (52Ϯ5% versus 51Ϯ7%, Pϭ0.001). Filling pressure estimate E/EЈ ratio improved from 14Ϯ5 at baseline to 12Ϯ4 at 3 months in the bone marrow cell group, whereas no improvement was observed in the placebo group (13Ϯ4 versus 13Ϯ5). The improvement in E/EЈ ratio was significantly larger in the bone marrow cell group (Pϭ0.008). Furthermore, the E/A peak flow ratio as assessed by MRI showed a significant increase in the bone marrow cell group as compared with the placebo group (ϩ0.16Ϯ0.25 versus Ϫ0.04Ϯ0.21, Pϭ0.01), which was mainly related to an increase in the early (E) peak flow rate in the bone marrow cell group (from 407Ϯ96 mL/s to 468Ϯ110 mL/s, Pϭ0.009 as compared with the placebo group). Conclusions-The current study demonstrates that intramyocardial bone marrow cell injection is associated with a beneficial effect on myocardial relaxation and filling pressures in patients with chronic myocardial ischemia. Clinical Trial Registration-URL: http://www.trialregister.nl. Unique identifier: NTR400/ISRCTN58194927.
B one marrow cell therapy has emerged as a potential therapeutic option for patients with chronic ischemic heart disease. Nonrandomized clinical studies demonstrated that intramyocardial injection of bone marrow-derived mononuclear cells is safe and feasible in patients with chronic myocardial ischemia. 1 Moreover, our recently published randomized, double-blinded, placebo-controlled trial 2 revealed that intramyocardial bone marrow cell injection is associated with improvements in myocardial perfusion and left ventricular (LV) systolic function in patients with chronic myocardial ischemia. These improvements were paralleled by a reduction in anginal symptoms and an increased quality of life.
Clinical Perspective on p 129
Experimental and clinical data have suggested that bone marrow cell injection may also have a beneficial effect on diastolic function. [3] [4] [5] [6] Diastolic dysfunction is often present in patients with coronary artery disease and is an important prognostic factor. 7 Therefore, more detailed determination of the effects on diastolic function is needed to further explore the functional benefit of bone marrow cell injection. In addition, such information could provide mechanistic insights and may have implications for future studies.
In a nonrandomized clinical study in patients with chronic myocardial ischemia, improvement in parameters of diastolic function was suggested after intramyocardial bone marrow cell injection. 8 On the basis of these results, the current substudy was conducted to investigate the effect of intramyocardial bone marrow cell injection on LV diastolic function in a randomized, double-blinded, placebo-controlled setting. Diastolic function was evaluated by echocardiographic measurement of parameters of filling pressure, myocardial relaxation, and ventricular compliance with the use of tissue Doppler imaging (TDI) and speckle-tracking strain analysis. In addition, changes in the transmitral flow pattern were evaluated using MRI.
Methods

Patient Selection and Study Protocol
The detailed study protocol of this randomized, double-blinded, placebo-controlled trial has been described previously. 2 In brief, patients with chronic ischemic heart disease were eligible for inclusion if they had refractory angina (Canadian Cardiovascular Society class III or IV despite optimal medical therapy) and stress-inducible ischemia on technetium-99m tetrofosmin singlephoton emission-computed tomography (SPECT). In all patients, bone marrow was aspirated from the iliac crest. Mononuclear cells were isolated by Ficoll density gradient centrifugation. After cell isolation, patients were randomly assigned in a 1:1 ratio to either intramyocardial injection of 100ϫ10 6 autologous bone marrowderived mononuclear cells or placebo solution (NaCl 0.9% with 0.5% human albumin). Intramyocardial injections were targeted at myocardial regions with stress-inducible ischemia (on SPECT) and were performed using the NOGA system (BDS, Cordis, Redwood City, CA) during cardiac catheterization. 2 The protocol was approved by the institutional ethics committee and complied with the declaration of Helsinki. The study was registered at the Dutch trial registry (www.trialregister.nl, No. NTR400/ISRCTN58194927).
Our primary end point was defined as the improvement in filling pressure estimate E/EЈ ratio. Furthermore, an extensive evaluation of diastolic function was performed using TDI and speckle-tracking strain analysis on echocardiography. Moreover, changes in the transmitral flow pattern of the LV were assessed using MRI.
Echocardiography
Images were obtained with patients in the left lateral decubitus position, using a commercially available system (Vivid Seven, General Electric-Vingmed, Milwaukee, WI). A 4-chamber apical tissue Doppler view was obtained. Color Doppler frame rates ranged between 115 to 160 frames per second (mean 148 frames per second), depending on the sector width of the range of interest, and pulse repetition frequencies were between 500 Hz and 1 kHz, resulting in aliasing velocities between 16 and 32 cm/s. The anteroposterior diameter of the left atrial (LA) was measured at end-systole on the M-mode image obtained from the parasternal long-axis view. LA volume was calculated using the biplane arealength method. 9 The LV volumes and LV ejection fraction were derived from the conventional apical 2-and 4-chamber images, using the biplane Simpson rule. 10 Mitral inflow was analyzed using pulsed Doppler recordings at the tips of the mitral leaflets to measure peak early filling velocity (E), deceleration time of early filling velocity, and peak atrial filling velocity (A). Pulmonary venous flow was recorded from the apical 4-chamber images, placing a sampling volume 1 cm into the right upper pulmonary vein to assess peak systolic velocity (S) and peak diastolic velocity (D).
Tissue Doppler Imaging
TDI parameters were measured by 2 independent observers from color-coded images of 3 consecutive heartbeats by offline analysis. The digital cineloops were analyzed using commercial software (Echopac 7.0.0, General Electric-Vingmed). Early diastolic velocity (EЈ) was measured at 4 LV basal segments by placing the sample volume in the LV basal portion of the septum, the lateral wall (using the 4-chamber view), the anterior wall, and the posterior wall (using the 2-chamber view). The described EЈ value is the average value of these 4 measurements. Late diastolic velocity (AЈ) was measured in the LV basal portion of the septum.
The respective intraobserver and interobserver variabilities were as follows: 0.1Ϯ0.1 cm/s and 0.4Ϯ0.1 cm/s for septal EЈ; 0.1Ϯ0.2 cm/s and 0.4Ϯ0.1 cm/s for AЈ; and 0.01Ϯ0.02 and 0.02Ϯ0.02 for the EЈ/AЈ ratio. 8
Speckle-Tracking Strain and Strain Rate Analysis
Two-dimensional speckle-tracking imaging allows angle-independent analysis of myocardial deformation. By frame-to-frame tracking of stable acoustic markers, or speckles, this method allows reliable and accurate assessment of myocardial strain. 11 Myocardial strain is a measure for the change in myocardial length and is presented as a percentage of the initial length. The temporal derivation of myocardial strain results in strain rate, which represents the rate of deformation (in s Ϫ1 ). 12 Strain and strain rate quantification was performed as previously described, 11, 13 by using a commercially available software (EchoPAC version 108.1.5, General Electric-Vingmed). Longitudinal strain and strain rate were assessed from the apical long-axis view and the 2-and 4-chamber views. Global strain was provided by the software with segmental strain values displayed in a bull's-eye summary consisting of 17 segments. The global strain rate value was defined as the average of the peak systolic strain rate values of 18 segments. For strain rate measurements, the software divides the apical segment in 2 segments, creating the 18 th segment. Because the injected and noninjected segments had been predefined using the generally accepted 17-segment model, 14 the 2 apical segments were merged to 1 segment by averaging the strain rate values for comparison of injected and noninjected segments. Thus, 1 apical segment was created that was geometrically identical with the apical segment in the 17-segment model used for strain analysis.
For assessment of diastolic strain rate indices, global strain rate curves were automatically assessed from the apical long-axis view and the 2-and 4-chamber views. Peak global strain rate during the isovolumic relaxation (GSR IVR ) period and during early diastole (GSR E ) were measured and averaged from the 3 apical views. 15 By calculating the ratio of peak transmitral E wave to GSR IVR (E/GSR IVR ), a novel parameter for estimation of LV filling pressure was obtained. 15
Magnetic Resonance Imaging
A 1.5-T Gyroscan ACS-NT MRI scanner (Philips Medical Systems, Best, The Netherlands) equipped with Powertrack 6000 gradients and a 5-element cardiac synergy coil was used. With the use of a balanced, fast-field echo sequence with parallel imaging (SENSE, acceleration factor 2), the heart was imaged from apex to base, with 10 to 12 imaging levels (dependent on the heart size) in the short-axis view. Typical parameters were a field of view of 400ϫ400 mm 2 , matrix of 256ϫ256 pixels, slice thickness of 10 mm, no slice gap, flip angle of 50°, time to echo of 1.82 ms, and time to repeat of 3.65 ms. The temporal resolution was 25 to 39 ms.
Phase-contrast flow velocity measurements across the mitral valve orifice were obtained using a fast-field echo sequence with retrospective gating. Velocity maps were acquired across the mitral orifice using a flip angle of 20°and an echo time of 10 to 12 ms. The image section had a thickness of 8 mm, a field of view of 350ϫ350 mm2, and consisted of 2 measurements of a 128ϫ128 acquisition matrix that was interpolated to a display matrix of 256ϫ256 pixels. Between 30 and 45 time frames (depending on the actual heart rate) were evenly distributed over the cardiac cycle, resulting in a temporal resolution of 25 to 30 ms. Total acquisition time was Ϸ3 minutes. The maximum phase shift of 180°was set to occur at a velocity of 100 cm/s. For a comprehensive diastolic function assessment, volumetric flow across the mitral valve was calculated by manually tracing the borders of the mitral valve in all time frames of the velocity map series, using the FLOW analytic software package (Medis, Leiden,
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The Netherlands). Automatic analysis of flow curves was performed after a manual indication of the start of early filling, peak early filling, peak atrial contribution to filling, and the end of filling as previously described. 16 The intraobserver and interobserver variabilities were 1Ϯ4 mL/s and 2Ϯ7 mL/s for the early (E) peak flow rate; 2Ϯ4 mL/s and 3Ϯ7 mL/s for the late (A) peak flow rate; and 0.01Ϯ0.02 and 0.02Ϯ0.03 for the E/A ratio, respectively. 8
Statistical Analysis
Data are reported as meanϮSD. Comparisons of continuous data were performed using the Student t test, and categorical variables were compared using the 2 test or Fisher exact test. Repeatedmeasures analysis of variance was used to study the relation between the allocated treatment and (changes in) continuous data at baseline and 3 months' follow-up. All analyses were performed in line with the intention-to-treat principle. For all paired tests, complete case analysis was performed. A probability value Ͻ0.05 was considered significant. Statistical analyses were performed with SPSS software (version 16.0, SPSS) and SAS statistical software (SAS Institute, Cary, NC). We applied linear regression analyses for the evaluation of (changes in) segmental strain and strain rate in relation to treatment allocation. We used the segment (and not the patient) as the unit of our analyses, and each patient contributed with 17 segments. We realized that the observations within a patient might not be entirely independent, and we used the method of generalized estimating equations to account for clustered data. Two linear regression models were developed, with the absolute changes in myocardial strain and strain rate as dependent variable, and treatment group and a variable that indicated if a segment was injected or not as determinants. We evaluated if the relation between injected versus noninjected segments and the absolute changes in myocardial strain and strain rate was modified by treatment allocation by including an interaction term in the model. Changes in strain and strain rate between injected segments and noninjected segments were further evaluated in both treatment groups separately.
Results
A total of 50 patients were randomly assigned to receive bone marrow cell injection (nϭ25) or placebo injection (nϭ25). The baseline characteristics of these patients are shown in Table 1 . The type and dose of medications remained unchanged during the entire study period. Systolic and diastolic blood pressures did not change during follow-up in either group (bone marrow cell group, 122Ϯ22 mm Hg systolic, Pϭ0.63, and 79Ϯ10 mm Hg diastolic, Pϭ0.59; placebo group, 115Ϯ17 mm Hg, Pϭ0.15, and 78Ϯ10 mm Hg, Pϭ0.26, respectively).
Procedural data and clinical outcome data of the cohort have been previously reported. 2 One patient died at 2.5 months' follow-up because of myocardial ischemia leading to acute heart failure. Therefore, paired echocardiography at baseline and 3 months' follow-up was available in 24 patients in the bone marrow cell group and 25 patients in the placebo group. Paired data of A, E/A ratio, AЈ, and EЈ/AЈ ratio were available in 22 patients in the cell group and 24 in the placebo group, due to atrial fibrillation in 2 bone marrow cell-treated patients and 1 placebo-treated patient.
MRI at baseline and 3 months' follow-up was available in 22 patients in the cell group and in 18 patients in the placebo group. Atrial fibrillation or insufficient flow measurements quality prevented reliable assessment of diastolic function in 3 patients in the cell group and 1 patient in the placebo group, as illustrated in the flow chart (Figure 1 ).
Global and Regional Systolic Function
After 3 months' follow-up, LV ejection fraction increased from 50Ϯ5% to 54Ϯ7% in the bone marrow cell group, which was a significant improvement as compared with the placebo group (Pϭ0.001). The increase in LV ejection fraction was mainly related to a decrease in LV end-systolic volume because no changes were observed in LV end-diastolic volume ( Table 2) . Table 3 summarizes the results of the evaluation of regional myocardial function. The observed improvements in global strain and global strain rate were significantly larger in the bone marrow cell group as compared with the placebo group (both Pϭ0.04). Using the linear regression model, no significant interaction was observed between treatment allocation and changes in segmental myocardial strain and strain rate because interaction terms were not significant (Pϭ0.07 and Pϭ0.23, respectively). Nonetheless, within-group analysis revealed that in bone marrow cell-treated patients, improvement in myocardial strain was significantly larger in injected segments as compared with noninjected segments (Pϭ0.008, Table 3 ). Similarly, the increase in myocardial strain rate was significantly greater in injected segments as compared with noninjected segments (Pϭ0.01). In placebotreated patients, improvements in myocardial strain and strain rate were not significantly larger in the injected segments as compared with the noninjected segments (Pϭ0.81 and Pϭ0.25, respectively).
Parameters of Diastolic Function With Echo
At 3 months' follow-up, filling pressure estimate E/EЈ ratio improved significantly in the bone marrow cell group as compared with the placebo group (Pϭ0.008), as shown in Figure 2 . No changes in LA size were detected in either treatment group (Table 2) .
A trend toward improvement was observed in transmitral E/A ratio (Pϭ0.06). As shown in Table 2 , this was mainly related to an increase in transmitral E-wave in bone marrow cell-treated patients. E-wave deceleration time and pulmonary venous flow patterns did not change in either group. Early diastolic velocity (EЈ) improved after bone marrow cell injection (Pϭ0.0001), whereas AЈ remained unchanged (Pϭ0.42), resulting in a significant increase in EЈ/AЈ ratio in the bone marrow cell group as compared with the placebo group (Pϭ0.0001, Table 2 ).
Paired measurements of GSR IVR and, consequently, filling pressure estimate E/GSR IVR , were available in 18 patients in the bone marrow cell group and in 22 patients in the placebo group. GSR E was available in all patients. Compared with placebo-treated patients, GSR IVR increased significantly in bone marrow cell-treated patients at 3 months' follow-up (Pϭ0.0005), resulting in a trend toward improvement in filling pressure estimate E/GSR IVR (Pϭ0.06). No significant changes were observed in GSR E ( Table 2 ).
Parameters of Diastolic Function With MRI
MRI-derived parameters of LV diastolic function significantly improved after 3 months' follow-up in bone marrow cell-treated patients as compared with placebo-treated patients (Table 4 ). Importantly, the increase in E/A peak flow ratio was significantly larger in the bone marrow cell group (Pϭ0.01), which was mainly based on an increase in the E peak flow rate, given that no improvement was observed in the A peak flow rate.
Discussion
The aim of the current study was to investigate the effect of intramyocardial bone marrow cell injection on LV diastolic function in patients with chronic myocardial ischemia. The present results demonstrate that bone marrow cell injection is associated with a modest but significant beneficial effect on both echocardiographic and MRI-derived parameters of LV diastolic function. The results of this study extend the previously reported observations that bone marrow cell injection improved myocardial perfusion, LV systolic function, and anginal symptoms in patients with chronic myocardial ischemia. 2 Although several studies assessed the effect of intramyocardial bone marrow cell injection on myocardial perfusion and LV systolic function, 2, 17 only limited data are available on the effect on diastolic function. In patients with acute myocardial infarction, an improvement in LV diastolic function was observed after intracoronary bone marrow cell infusion in a substudy from the BOOST trial, 3 which was partially sustained at 18 months' follow-up but not at 5-year follow-up. 6 In a recent study using a pig model of chronic myocardial ischemia, Schneider et al 5 demonstrated that intramyocardial bone marrow cell injection with the use of the NOGA system could improve parameters of LV diastolic function. Furthermore, in a nonrandomized clinical study van Ramshorst et al Diastolic Function After Cell Therapy from our group in patients with chronic myocardial ischemia, improved myocardial relaxation was observed after intramyocardial bone marrow cell injection. 8 The current study is the first to confirm the beneficial effect of intramyocardial bone marrow cell injection on diastolic function in a randomized, double-blinded, placebo-controlled clinical trial in patients with chronic myocardial ischemia. In the present study, the E/EЈ ratio was chosen as a primary end point of the study because this parameter has been shown to provide a reliable estimate of LV filling pressures. 18 At baseline, patients had high-normal LV filling pressures and modestly impaired myocardial relaxation, as evidenced by an EЈ of 5.5Ϯ1.4 in the bone marrow cell group and 5.6Ϯ1.4 in the placebo group (Pϭ0.73). Filling pressure estimate E/EЈ showed a modest but significant improvement in the bone marrow cell group as compared with the placebo group. The improvement in filling pressure was confirmed by a decrease in speckle tracking-derived filling pressure estimate E/GSR IVR .
Filling pressures are mainly determined by volume load on one side and ventricular compliance and myocardial relaxation on the other side. 18 Because myocardial relaxation improved, as indicated by EЈ, diastolic strain rate and MRIderived flow measurements, it is conceivable that the decrease in filling pressure is mainly related to the improvement in myocardial relaxation. Of note, parameters of ventricular compliance such as deceleration time and peak atrial filling did not reveal any changes in ventricular compliance. Although filling pressure estimates were decreased at 3 months' follow-up, no decrease in LA size was observed. This may be related to the short follow-up period, which is probably too short to observe structural changes of the LA. Nonetheless, it must be noted that the observed improvements in filling pressure estimates may be too modest to be accompanied by structural changes in the LA.
Diastolic dysfunction, and impaired myocardial relaxation in particular, has been established as an early consequence of myocardial ischemia. 19, 20 All patients included in the current study had chronic myocardial ischemia as documented using SPECT, caused by severe coronary artery disease. Hence, it is likely that the modestly impaired myocardial relaxation at baseline, resulting in high-normal filling pressures, is a consequence of the presence of myocardial ischemia.
Experimental studies have demonstrated that bone marrow cell injection may enhance neovascularization through secretion of proangiogenic cytokines and physical incorporation of the injected cells into new capillaries or in perivascular cells. 21, 22 In line with these observations, the present trial documented an improvement in myocardial perfusion and a reduction in myocardial ischemia after intramyocardial bone marrow cell injection. 2 In patients undergoing coronary artery bypass grafting, improvements in myocardial relaxation and filling pressures were reported by Carluccio et al. 23 Accordingly, it may be hypothesized that the observed improvements in myocardial relaxation and, subsequently, filling pressures, are secondary to enhanced myocardial perfusion. From a mechanistic point of view, the current data support this hypothesis because the enhanced myocardial perfusion would be expected to improve active processes such as myocardial relaxation rather than altering myocardial structure and ventricular compliance.
The effect of bone marrow cell injection on LV diastolic function was evaluated using both MRI and echocardiography. Phase-contrast flow velocity mapping by MRI is a well-validated automated technique for the evaluation of diastolic function. 24, 25 By measuring flow velocity as well as flow volumes across the mitral valve orifice, it allows reliable measurement of peak early filling, peak atrial contribution to filling, and the end of filling. In the present study, flow velocity mapping detected an increase in the E/A peak flow ratio, indicating improved myocardial relaxation.
In the present study, evaluation of regional myocardial function using speckle-tracking strain analysis documented significant improvements in global strain and strain rate after bone marrow cell injection. In a multivariable linear regression model, no significant interaction was observed between treatment allocation and improvement in segmental strain and strain rate, respectively. Nonetheless, within-group analysis revealed that the improvement in LV systolic function in bone marrow cell-treated patients is predominantly caused by enhanced myocardial function in the injected myocardial segments. This observation is in line with the results from the study of Herbots et al 26 in patients with acute myocardial infarction, which demonstrated improved recovery of regional function in the infarct-related segments after bone marrow cell transfusion in the infarct-related artery. Of note, the patients in the present study were not recovering from acute myocardial infarction but had stable coronary artery disease resulting in chronic myocardial ischemia. Therefore, this observation suggests that bone marrow cells can not only stimulate an ongoing recovery process after myocardial infarction but may also initiate focal improvement in a stable Figure 2 . Individual changes in filling pressure estimate E/EЈ ratio. In the bone marrow cell group, filling pressure estimate E/EЈ ratio improved from 14Ϯ5 at baseline to 12Ϯ4 at 3 months. In the placebo group, no improvement was observed (13Ϯ4 versus 13Ϯ5). The improvement in the bone marrow cell group was significantly larger as compared with the improvement in the placebo group (Pϭ0.008). situation such as chronic myocardial ischemia. This might be regarded as an encouraging finding with regard to cell-based treatment strategies for stable angina, ischemic heart failure, or nonischemic cardiomyopathy. In addition, the regional effect observed in the injected segments suggests that the amount of cells that is retained in the myocardium is apparently sufficient to induce these objective improvements in regional function, which is an important observation with regard to the doubts that have been raised with regard to the engraftment rate and cell survival after injection. 27 The results of the present study have several implications. Importantly, this study demonstrates that the functional benefit of bone marrow cell injection is not confined to myocardial perfusion and systolic function. Although only modest improvements in diastolic function were observed, the effects on diastolic function may be considered in the design of future studies. In addition, because diastolic dysfunction is a prognostic factor, future studies must evaluate whether the improvement in diastolic function is related to better outcome in these patients with severe coronary artery disease.
The present study has several limitations. First, a minority of the patients included in the randomized trial was not available for inclusion in the current substudy because of atrial fibrillation, the inability to undergo MRI scanning, or insufficient flow measurements quality. However, the baseline characteristics of the patients in this substudy were comparable with those of the entire study cohort. Second, the follow-up period of the present study is relatively short to monitor changes in diastolic function because changes in ventricular compliance or LA volume may be evident after a longer follow-up period. In addition, in the current design it is not possible to document whether the improvement in diastolic function will be sustained over time after 3 months' follow-up. Finally, invasive measurements were not used in the current study, and diastolic function was evaluated using noninvasive estimates of diastolic function.
In summary, the current substudy of the randomized, double-blinded, placebo-controlled trial from our group demonstrates that intramyocardial injection of autologous bone marrow-derived mononuclear cells is associated with a beneficial effect on both MRI-derived and TDI-derived parameters of diastolic function in patients with chronic myocardial ischemia.
